A Study to Evaluate the Safety and Efficacy of L19TNF With Alkylating Chemotherapy for Patients With Recurrent IDH-mutant Astrocytoma or Oligodendroglioma
← catalyst calendarNCT07120984 · readout in 895 d
Sponsored by Philogen S.p.A. (industry) · PHIL.MI — their whole pipeline →.
Phase
Phase 2
Status
Not yet recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
52estimated
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-01-30 | estimated | When the study began enrolling |
| Primary completion | 2029-01-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-01-30 | estimated | The whole study's end, after follow-up |
| First posted | 2025-08-13 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-08-13 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Glioma
Interventions
- Biological: L19TNF
- Biological: L19TNF and TMZ
- Biological: L19TNF and CCNU
- Biological: L19TNF monotherapy
- Biological: L19TNF and TMZ in recurrent astrocytoma
- Biological: L19TNF and CCNU in recurrent astrocytoma
- Biological: L19TNF monothery in recurrent oligodendroglioma
Primary outcome
what the primary-completion date above is the date OFProgression-free survival (PFS)
measured The PFS rate will be assessed at 12 months (PFS-12) in IDH mutant astrocytoma and in oligodendroglioma.
Permalink · PHIL.MI's whole pipeline · Catalyst calendar · Every registered study · What changed